Daehwa receives U.S. PTO notice of allowance for oral paclitaxel

Published: 2011-11-11 06:56:00

Updated: 2011-11-11 06:56:00

Daehwa said Wednesday that its patent application entitled “Solubilizing composition for paclitaxel and its manufacturing method” has received notice of allowance from the U.S. Patent and Trademark Office.

Paclitaxel is an anticancer agent widely applied in the treatment of advanced breast, lu...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK